Esperion to Participate in Two Upcoming Virtual Investor Conferences
Esperion (NASDAQ: ESPR) has announced participation in two virtual conferences in May 2021. The first is the Bank of America 2021 Healthcare Conference on May 13, 2021, at 10:15 a.m. ET, featuring presentations and 1:1 investor meetings. The second event, the Morgan Stanley Life After Covid Thematic Conference II, is set for May 20, 2021, at 11:15 a.m. ET. Live audio webcasts will be accessible via the investor relations section of their website, with replays available for 90 days.
- None.
- None.
ANN ARBOR, Mich., May 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of May.
| Event: | Bank of America 2021 Healthcare Conference |
| Date: | May 13, 2021 |
| Format: | Presentation & 1:1 Investor meetings |
| Time: | 10:15 a.m. ET |
| Event: | Morgan Stanley Life After Covid Thematic Conference II |
| Date: | May 20, 2021 |
| Format: | Presentation & 1:1 Investor meetings |
| Time: | 11:15 a.m. ET |
Live audio webcasts of these events can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/. Replays of the webcasts will be archived on the Company's website for 90 days following the events.
ESPERION Therapeutics
ESPERION is The Lipid Management Company. Our goal is lipid management for everybody, that’s why we work hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
ESPERION Therapeutics’ Commitment to Patients with Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and cholesterol in and on artery walls (known as atherosclerosis), potentially leading to cardiovascular events, including heart attack and stroke. In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C. There are approximately 18 million people in the U.S. living with elevated levels of LDL-C despite taking maximally tolerated lipid-modifying therapy — including individuals considered statin averse — leaving them at high risk for cardiovascular events1. In the United States, more than 50 percent of atherosclerotic cardiovascular disease (ASCVD) patients and heterozygous familial hypercholesterolemia (HeFH) patients who are not able to reach their guideline recommended LDL-C levels with statins alone need less than a 40 percent reduction to reach their LDL-C threshold goal2.
ESPERION's mission as the Lipid Management Company is to deliver oral, once-daily medicines that complement existing oral drugs to provide the additional LDL-C lowering that these patients need.
References
(1) ESPERION market research on file: research project interviewing 350 physicians. ESPERION Therapeutics, Inc. Sept-Oct 2018.
(2) Data on file: analysis of NHANES database. ESPERION Therapeutics, Inc. 2018.
Investor Contact:
Kaitlyn Brosco
Esperion
corporateteam@esperion.com
FAQ
What is the date of the Bank of America 2021 Healthcare Conference for Esperion?
What time will Esperion present at the Morgan Stanley Life After Covid Thematic Conference II?
Where can I find the live audio webcasts of Esperion's conferences?
How long will the webcasts of Esperion's presentations be available?
What is the focus of Esperion as a company?
